Patients with multiple myeloma treated with idecabtagene vicleucel, known as “ide-cel,” a chimeric antigen receptor (CAR) T-cell therapy, had no difference in overall survival outcomes regardless of race and ethnicity, according to a study published in Blood Advances.
Generic industry group sues Illinois over drug price law
The Association for Accessible Medicines sued Illinois Attorney General Kwame Raoul over a law that the Washington, DC-based trade group says would give the state
January 26, 2024